Back to RGEN overview

RGEN Repligen PE ratio, current and historical analysis

The current PE ratio for Repligen stock as of Jun 12, 2024 is 510.25. This is calculated based on the current EPS of $0.28 and the stock price of $142.87 per share. The P/E ratio has increased by 98% from the past four quarters average of 257.5.

RGEN PE ratio history

How has RGEN's PE ratio performed in the past

The average historical PE ratio of Repligen for the last ten years is 126.41. The current PE ratio of 510.25 is comparable to the historical average. Over the past ten years, RGEN's PE ratio was at its highest in the Mar 2024 quarter at 656.86, when the stock price was $183.92 and the EPS was $0.28. The lowest value was in the Jun 2014 quarter, when it reached 44.69 with a price of $22.79 and an EPS of $0.51.

Average
126.41
Median
107.51
Minimum
44.69
Maximum
656.86

Repligen PE ratio by year

Maximum annual increase: 374.34% in 2023

Maximum annual decrease: -55.54% in 2022

Year PE ratio Change
2023 239.73 374.34%
2022 50.54 -55.54%
2021 113.67 -32.38%
2020 168.1 -20.04%
2019 210.23 51.47%
2018 138.79 183.07%
2017 49.03 -44.32%
2016 88.06 -12.85%
2015 101.04 27.58%
2014 79.2 196.07%

RGEN average PE ratio chart

What is the average PE ratio of RGEN for the past years

RGEN's current P/E ratio is above the 3, 5 and 10-year historical averages.

3-year avg
140.04
5-year avg
154.54
10-year avg
126.41
15-year avg
118.67

RGEN PE vs peers

What is RGEN's PE ratio compared to its peers

Compared to its peer stocks TMO and GE, RGEN's PE ratio stands higher. Repligen's current PE ratio of 510.25 is comparable to the average of its peer group, which is 48.03.

Stock name PE ratio Market cap
CRL Charles River Laboratories International Inc 24.85 $10.94B
NBIX Neurocrine Biosciences Inc 36.14 $13.71B
TMO Thermo Fisher Scientific Inc 36.59 $218.58B
GE General Electric Co 50.39 $170.42B
TECH BIO-TECHNE Corp 60.54 $12.12B
BMRN Biomarin Pharmaceutical Inc 77.28 $16B
RGEN Repligen Corp 449.79 $7.04B
NVAX Novavax Inc N/A $2.11B
BMY Bristol Myers Squibb Co N/A $84.08B
PFE Pfizer Inc N/A $156.68B
SGMO Sangamo Therapeutics Inc N/A $115.5M

Frequently asked questions

What is Repligen's PE ratio?

As of Jun 12, 2024, RGEN stock has a price to earnings ratio of 510.25.

What is the 3-year average PE ratio for Repligen (RGEN)?

Over the last 3 years, the average price to earnings ratio for RGEN stock is 140.04.

What is the 5-year average PE ratio for Repligen (RGEN)?

Over the last 5 years, the average price to earnings ratio for RGEN stock is 154.54.

What is the highest PE ratio for RGEN?

Over the last ten years, the quarterly PE ratio reached a historic high of 656.86 in the Mar 2024 quarter.

How does the current PE ratio for RGEN compare to its historical average?

The current price to earnings ratio of RGEN is 304% higher than the 10-year historical average.

Why is Repligen's PE ratio so high?

RGEN's PE ratio of 510.25 is considered high because the company's stock price is trading at a higher multiple of earnings.

How is RGEN's PE ratio calculated (Repligen PE ratio formula)?

The PE ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (Jun 12, 2024), Repligen's stock price is $142.87. The earnings per share for the trailing twelve months (TTM) ending Mar 2024 is $0.28. Therefore, Repligen's P/E ratio for today is 510.25. PE RATIO(510.25) = STOCK PRICE($142.87) / TTM EPS($0.28)

All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.